mass spectrometry raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-12-27. Anything still debated is marked as such rather than presented as settled.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
=== Banana equivalent dose === The origin of the concept of using a banana equivalent dose (BED) as a benchmark is unknown. In 1995, Gary Mansfield of the Lawrence Livermore National Laboratory found the Banana Equivalent Dose (BED) to be very useful in explaining radiation risks to the public. It is not a formally used dose. The banana equivalent dose is the dose of ionizing radiation to which a person is exposed by eating one banana. Bananas contain potassium. Natural potassium consists of 0.0117% of the radioactive isotope 40K (potassium-40) and has a specific activity of 30,346 becquerels per kilogram, or about 30 becquerels per gram. The radiation dose from eating a banana is about 0.1 μSv. The value of this reference dose is given as "1" and thus becomes the "unit of measurement" banana equivalent dose. Consequently, other radiation exposures can be compared to the consumption of one banana. For example, the average daily total radiation exposure of a person is 100 banana equivalent doses. At 0.17 mSv per year, almost 10 percent of natural radioactive exposure in Germany (an average of 2.1 mSv per year) is caused by the body's own (vital) potassium. The banana equivalent dose does not take into account the fact that no radioactive nuclide is accumulated in the body through the consumption of potassium-containing foods. The potassium content of the body is in homeostasis and is kept constant.
== Taxonomy == Although unnamed Ambrosiella-like fungi had previously been documented from the galleries and mycangia of native X. crassiusculus populations in central Japan, A. roeperi was first described as a novel species of ambrosia fungus by Harrington and McNew in 2014 based on isolations from beetles collected and trapped in the eastern United States, where it is invasive. It has not been assigned a common name at the time of this writing. All Ambrosiella are ambrosia beetle symbionts and belong to the family Ceratocystidaceae, which, where sexual stages are recognized, produce round, ostiolate (with a pore) fruiting bodies for their ascospores with a fine peridium (outer layer) and aseptate (lacking crosswalls) paraphyses (sterile tissue found among – and arising from the same surface as – spore-bearing cells). This family also includes Ceratocystis, representing several plant pathogens and sap-staining fungi, often transported by insects (including scolytine beetles); Chalaropsis, encompassing a few economically insignificant root diseases; Huntiella, primarily made up of saprobes associated with lesions on trees, transported by sap beetles and in one case an Ips bark beetle; Thielaviopsis, containing various agents of disease affecting monocots; Davidsoniella, comprising several species of tree pathogens, and Endoconidiophora, growing on conifers, producing disease and/or sap stain, and also often acting as a bark beetle associate.
=== Pain === KOR agonists have been clinically employed as analgesics, with examples including butorphanol, nalbuphine, levorphanol, levallorphan, pentazocine, phenazocine, and eptazocine. Unlike MOR agonists, KOR agonists do not cause respiratory depression and have lower abuse potential, but centrally-mediated side effects such as dysphoria, hallucinations, and dissociation have limited their clinical utility. Nalorphine and nalmefene are dual MOR antagonists and KOR agonists used clinically as antidotes for opioid overdose, but the specific role of KOR activation to their efficacy remains uncertain as KOR agonists do not reverse respiratory depression induced by MOR activation and thus cannot serve as standalone antidotes for this purpose. Peripherally selective KOR agonists display analgesic efficacy mediated through anti-inflammatory effects on immune cells and nociceptors. CR665 and difelikefalin (CR845, FE-202845) have been investigated clinically; marking the first peripherally-restricted KOR agonist to reach regulatory approval, though none have yet been approved specifically for pain indication. Recent evidence supports the therapeutic potential of mixed KOR/MOR agonists and KOR-biased ligands as adjuncts to conventional analgesics in inflammatory and cancer pain, with particular promise for chronic neuropathic pain syndromes.
== Pharmacology == 18-MC is a α3β4 nicotinic antagonist and, in contrast to ibogaine, has no affinity at the α4β2 subtype nor at NMDA-channels nor at the serotonin transporter, and has significantly reduced affinity for sodium channels and for the σ receptor, but retains modest affinity for μ-opioid receptors where it acts as an agonist, and κ-opioid receptors. The sites of action in the brain include the medial habenula, interpeduncular nucleus, dorsolateral tegmentum and basolateral amygdala. (±)-18-MC competitively inhibits α9α10 nAChRs with potencies higher than that at α3β4 and α4β2 nAChRs and directly blocks CaV2.2.
Sources: en.wikipedia.org
Laser-assisted new attachment procedure (LANAP) is a surgical therapy for the treatment of periodontitis, intended to work through regeneration rather than resection. This therapy and the laser used to perform it have been in use since 1994. It was developed by Robert H. Gregg II and Delwin McCarthy. In LANAP surgery, a variable free-running pulsed neodymium:yttrium-aluminum-garnet (Nd:YAG) laser at 1064 nm wavelength is used by a dentist or periodontist to treat the periodontal pocket. The laser is intended to selectively remove diseased or infected pocket epithelium from the underlying connective tissue. The Nd:YAG laser has been shown to reduce levels of microbial pathogens in periodontal pockets and vaporize the pocket-lining epithelium without causing damage to the underlying connective tissue.
Heterocyclic amines, also sometimes referred to as HCAs, are chemical compounds containing at least one heterocyclic ring, which by definition has atoms of at least two different elements, as well as at least one amine (nitrogen-containing) group. Typically it is a nitrogen atom of an amine group that also makes the ring heterocyclic (e.g., pyridine), though compounds exist in which this is not the case (e.g., the drug zileuton). The biological functions of heterocyclic amines vary, including vitamins and carcinogens. Carcinogenic heterocyclic amines are created by high temperature cooking of meat and smoking of plant matter like tobacco. Some well known heterocyclic amines are niacin (vitamin B3), nicotine (psychoactive alkaloid and recreational drug), and the nucleobases that encode genetic information in DNA.
==== Notice provisions ==== The amendments required unions and employers to give 80 days' notice to each other and to certain state and federal mediation bodies before they may undertake strikes or other forms of economic action in pursuit of a new collective bargaining agreement; it did not, on the other hand, impose any "cooling-off period" after a contract expired.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.